These are the references used in the book, in order of citation.
1. Larson RM. (2004). Science in the Ancient World: An Encyclopedia. ABC-CLIO: Santa Barbara, CA; 29-30.2. Debus AG. (1970). Johann Hoachim Becher. In: Gillispie CC, ed. Dictionary of Scientific Biography. Vol. 1. Charles Scribner’s Sons: New York.3. Conant JB, ed. (1950). The Overthrow of Phlogiston Theory: The Chemical Revolution of 1775–1789. Harvard University Press: Cambridge, MA; 14.4. Thompson JJ. (1904). On the structure of the atom: an investigation of the stability and periods of oscillation of a number of corpuscles arranged at equal intervals around the circumference of a circle; with application of the results to the theory of atomic structure. Philos Magazine, Series 6. 7(39):237-265.5. Winkler KP, ed. (1996). John Locke, An Essay Concerning Human Understanding. Hackett Publishing Company: Indianapolis, IN; 33-36.6. Aristotle (350 BC). On the soul (de anima). In: Aristotle. Vol. 8 (1936). Hett, WS, trans. Loeb Classical Library, William Heinemann: London; 1-203.7. Freud S. (1940). An outline of psycho-analysis (the standard edition). In: Strachey J, ed. Complete Psychological Works of Sigmund Freud. WW Norton: New York.8. Adler A. (1956). In: Ansbacher, HL and Ansbacher RR, eds. The Individual Psychology of Alfred Adler. Harper Torchbooks: New York.9. Kendler KS. (1983). Overview: a current perspective on twin studies of schizophrenia. Am J Psychiatry. 140:1413-1425.10. Bertelsen A, Harvald B, Hauge M. (1977). A Danish twin study of manic-depressive disorders. Br J Psychiatry. 130:330-351.11. Wender PH, Kety SS, Rosenthal D, Schulsinger F, Ortmann J, Lunde I. (1986). Psychiatric disorders in the biological and adoptive families of adopted individuals with affective disorders. Arch Gen Psychiatry. 43:923-929.12. Snyder SH. (1986). Drugs and the Brain. Scientific American Books/WH Freeman: New York.13. Purves D, Augustine GJ, Fitzpatrick D, et al. (2004). Neuroscience. 4th ed. Sinauer Associates, Inc.: Sunderland, MA.14. Restak RM. (1984). The Brain. Bantam Books: New York.15. Qian Y, Melikian HE, Rye DB, Levey AI, Blakely RD. (1995). Identification and characterization of antidepressant-sensitive serotonin transporter proteins using site-specific antibodies. J Neurosci. 15:1261-1274.16. Torres GE, Gainetdinov RR, Caron MG. (2003). Plasma membrane monoamine transporters: structure, regulation and function. Nat Rev Neurosci. 4(1):13-25.17. Wade NJ, Brozek J. (2001). Purkinje’s Vision–The Dawning of Neuroscience. Lawrence Erlbaum Assoc.: London.18. Golgi C. (1906). In: Nobel Lectures, Physiology or Medicine 1901-1921. (1967). Elsevier Publishing Company: Amsterdam.19. Cajal R. (1906). In: Nobel Lectures, Physiology or Medicine 1901-1921. (1967). Elsevier Publishing Company: Amsterdam.20. Sherrington CS. (1920). The Integrative Action of the Nervous System. New Haven Yale Press: New Haven, CT.21. Raju TN. (1999). The Nobel chronicles. 1936: Henry Hallett Dale (1875-1968) and Otto Loewi (1873-1961). Lancet. 353(9150): 416.22. Fields DR (2009). The Other Brain. Simon & Schuster: New York.23. Rizzoli SO, Betz WJ (2005). Synaptic vesicle pools. Nat Rev Neurosci. 6(1):57-69. 24. Weihe E, Eiden LE. (2000). Chemical neuroanatomy of the vesicular amine transporters. FASEB J. 14(15):2435-2449.25. Hoffer A. (2005). Adventures in Psychiatry. The Scientific Memoirs of Dr. Abram Hoffer. KOS Publishing: Toronto.26. Wittenborn JR, Weber ESP, Brown M. (1973). Niacin in the long-term treatment of schizophrenia. Arch Gen Psychiatry. 28:308-315.27. McGinnis W, Audhya T, Walsh WJ, et al. (2008). Discerning the mauve factor, part 1. Altern Ther Health Med. 14(2):40-50.28. Pfeiffer CC. (1976). Mental and Elemental Nutrients: A Physician’s Guide to Nutrition and Health Care. Keats Publishing: New Canaan, CT.29. Pfeiffer CC, Mailloux BS, Forsythe BA. (1970). The Schizophrenias: Ours to conquer. Bio- Communications Press: Wichita, KS.30. Walsh WJ, Glab LB, Haakenson ML. (2004). Reduced violent behavior following biochemical therapy. Physiol Behav. 82:835-839.31. Owen CA. (1982). Biochemical aspects of copper, occurrence, assay, and interrelationships. Noyes Publications: Park Ridge, NJ.32. Linder MC. (1991). Biochemistry of Copper. Plenum Press: New York.33. Morgan RF, O’Dell BL. (1977). Effect of copper deficiency on the concentrations of catecholamines and related enzyme activities in the rat brain. J Neurochem. 28:207-213.34. Prohaska JR, Snith TL. (1982). Effect of dietary or genetic copper deficiency on brain catecholamines, trace metals, and enzymes in the rat brain. J Nutr. 112:1706-1717.35. Combs GF. (2008). The Vitamins: Fundamental Aspects in Nutrition and Health. Elsevier: San Diego, CA.36. Food and Nutrition Board, Institute of Medicine. (2001). Dietary Reference Intakes: Vitamins. The National Academies Press: Washington, DC.37. Berger M, Gray JA, Roth BL. (2009). The expanded biology of serotonin. Ann Rev Med. 60:355-366.38. Elsworth JD, Roth RH. (1997). Dopamine synthesis, uptake, metabolism, and receptors: relevance to gene therapy of Parkinson’s disease. Exp Neurol. 144(1): 4-9.39. Tapia R. (1975). Biochemical pharmacology of GABA in CNS. In: Iversen LL, Iversen SD, Snyder SH, eds. Handbook of Psychopharmacology. Vol 4. Plenum Press: New York; 1-58.40. Sauberlich HE. (1999). Laboratory Tests for the Assessment of Nutritional Status. CRC Press: New York.41. Prasad AS. (1993). Biochemistry of Zinc. Plenum Press: New York.42. Walsh WJ, Rehman F. (1997). Methylation syndromes in mental illness. Abstracts: Society for Neuroscience 27th Annual Meeting (pt 2). New Orleans, LA, October 25-29.43. Feighner JP. (1999). Mechanism of action of antidepressant medications. J Clin Psychiatry. 60(suppl 4):4-11.44. Edelman E. (2009). Natural Healing for Bipolar Disorder. Borage Books: Eugene, OR.45. Murray RK, Granner DK, Mayes PA, Rodwell VW. (1993). Harper’s Biochemistry. 23rd ed. Appleton & Lange: Norwalk, CT; 49-59.46. Berger SL, Kouzarides T, Schickhatter R, Shilatifard A. (2009). An operational definition of epigenetics. Genes Dev. 23(7):781-783.47. Bird A. (2007). Perceptions of epigenetics. Nature. 447(7143):396-398.48. Tsankova N, Renthal W, Kumar A, Nestler EJ. (2007). Epigenetic regulation in psychiatric disorders. Nat Rev Neurosci. 8(5):355-367.49. Ng HH, Gurdon JB. (2008). Epigenetic inheritance of cell differentiation status. Cell Cycle. 7(9):1173-1177.50. Luger K, Mader AW, Richmond RK, Sargent DF, Richmond TJ. (1997). Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature. 389(6648):251-260.51. Roth TL, Sodhi M, Kleinmer JE. (2009). Epigenetic mechanisms in schizophrenia. Biochem Biophy Acta. 1790(9):869-877.52. Flight M. (2007). Epigenetics: methylation and schizophrenia. Nat Rev Neurosci. 8:910-994.53. Suzuki MM, Bird AP. (2008). DNA methylation landscapes: provocative insights from epigenomics. Nat Rev. Genet. 9(6):465-476.54. Kouzarides T. (2007). Chromatin modifications and their function. Cell. 128(4):693-705.55. Miranda TB, Jones PA. (2007). DNA methylation: The nuts and bolts of repression. J Cell Physiol. 213(2):384-390.56. Latchman DS. (1997). Transcription factors: an overview. Int J Biochem. Cell Biol. 29(12):1305-1312.57. Nelson DL, Cox MM. (2000). Lehninger Principles of Biochemistry. 3rd ed. Worth Publishing: New York.58. Avalos JL, Bever KM, Wolberger C. (2005). Mechanism of sirtuin inhibition by nicotinamide: altering the NAD+ cosubstrate specificity of a Sir2 enzyme. Mol Cell. 17(6):855-868.59. Luka Z, Moss F, Loukachevitch LV, Bornhop DJ, Wagner C. (2011). Histone demethylase LSD1 is a folate-binding protein. Biochemistry. 50(21):4750-4756.60. Jenuwein T, Allis CD. (2001). Translating the histone code. Science. 293(5532):1074-1080.61. Preskorn SH, Ross R, Stanga CY. (2004). Selective serotonin reuptake inhibitors. In: Antidepressants: Past, Present and Future. Springer: Berlin; 241-262.62. Sharma RP. (2005). Schizophrenia, epigenetics and ligand-activated nuclear reactions: a framework for chromatin therapeutics. Schizophr Res. 72(2-3):77-90.63. Petronis A. (2004). The origin of schizophrenia: genetic thesis, epigenetic antithesis, and resolving synthesis. Biol Psychiatry. 55:965-970.64. Bilstufi G, VanDette E, Matsui S, Smiraglia DJ. (2010). Mild folate deficiency induces genetic and epigenetic instability and phenotype changes in prostate cancer cells. BMC Biol. 8:6.65. Maulik N, Maulik G, eds. (2011). Nutrition, Epigenetic Mechanisms, and Human Disease. CRC Press: Boca Raton, FL.66. Pogribny IP, Tryndyak VP, Muskhelishvili L, Rusyn I, Ross SA. (2007). Methyl deficiency, alterations in global histone modifications, and carcinogenesis. J Nutr. 137:216S-222S.67. Litt MD, Simpson M, Recillas-Targa F, Prioleau MN, Felsenfeld G. (2001). Transitions in histone acetylation reveal boundaries of three separately regulated neighboring loci. EMBO J. 20(9):2224-2235.68. Bredy TW, Sun Ye, Kobor MS. (2010). How the epigenome contributes to the development of psychiatric disorders. Dev Psychobiol. 52(4):331-342.69. James SJ, Melnyk SB, Jernigan S, Janak L, Cutler P, Neubrander JM. (2004). Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. Amer J Clin Nutr. 80:1611-1117.70. Deth RC. (2003). Molecular Origins of Attention: The Dopamine-Folate Connection. Kluwer Academic Publishers: Norwell, MA.71. Walsh WJ. (2010). Oxidative stress, undermethylation, and epigenetics—The Bermuda triangle of autism. The Autism File. 35:30-35.72. Walsh WJ. (July 23, 2010). Nutrient therapy for mental illness. Irish Medical Times. Available at www.imt.ie/opinion/guests/2010/07/nutrient-therapy-for-mental-illness.html.73. American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorders, Fourth Edition (Text Revision). American Psychiatric Press: Washington, DC.74. Jablonka E, Gal R. (2009). Transgenerational Epigenetic Inheritance: Prevalence, Mechanisms, and Implications for the Study of Heredity and Evolution. Q Rev Biol. 84(2):131-176.75. Evans K, McGrath J, Milns R. (2003). Searching for schizophrenia in ancient Greek and Roman literature: a systematic review. Acta Psychiatrica Scandinavica. 107(5):323-330.76. Alexander FG, Selesnick ST. (1966). The History of Psychiatry. An Evaluation of Psychiatric Thought and Practice from Prehistoric Times to the Present. Harper and Row: New York.77. Kruger S, Braunig P. (2000). Ewald Hecker, 1843-1900. Am J Psychiatry. 157:1220.78. Meyer A. (1910). The nature and conception of dementia praecox. J Abnorm Psychol. 5(5):247-285.79. Kraepelin E. (1907). Text book of psychiatry. 7th ed. Diefendorf AR, trans. Macmillan: London.80. Kuhn R. (2004). Eugen Bleuler’s concepts of psychopathology. Hist Psychiatry. 15(3):361-366.81. Freud S, trans, Brill AA. (1938). The Basic Writings by Sigmund Freud. Random House: New York.82. Adler A, trans, Brett C. (1992). Understanding Human Nature. Oneworld Publications Ltd.: London.83. Jung CJ, trans, Adler G, Hull RFC. (1970). The Collected Works of C. J. Jung. Vol 1. Princeton University Press: Princeton, NJ.84. Schildkraut JJ. (1965). The catecholamine hypothesis of affective disorders: a review of supporting evidence. Amer J Psychiatry. 122:609-622.85. Slater E, Cowle V. (1971). The Genetics of Mental Disorders. Oxford University Press: London.86. Mathews M, Muzina DJ. (2007). Atypical antipsychotics: new drugs, new challenges. Cleve Clin J Med. 74(8):597-606.87. Lieberman JA, Stroup TS, McEvoy JP, et al. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. NEJM. 353(12):1209-1223.88. Ho BC, Andersen NC, Ziebell S, Pierson R, Magnotta V. (2011). Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. Arch Gen Psych. 68:2.89. Carlsson A. (2003). Half-century of neurotransmitter research: impact on neurology and psychiatry. In: Jörnvall H, ed. Nobel Lectures in Physiology or Medicine 1996-2000. World Scientific Publishing Co.: Singapore.90. Carlsson A. (1987). The dopamine hypothesis of schizophrenia 20 years later. In: Häffler H, Gattaz WF, Janzarik W, eds. Search for the Cause of Schizophrenia. Springer-Verlag: Berlin Heidelberg; 223-235.91. Olney JW, Newcomer JW, Farber BB. (1999). NMDA receptor hypofunction model of schizophrenia. Journal of Psychiatric Research, 33, 523-533.92. Javitt DC, Zukin SR. (1991). Recent advances in the phencyclidine model of schizophrenia Am J Psychiatry. 148:1301-1308.93. Lane HY, Chang YC, Liu YC, Chiu CC, Tsai GE. (2005). Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia—a randomized, double-blind, placebo controlled study. Arch Gen Psychiatry. 62:1196-1204.94. Mahadik SP, Mukherjee S. (1996). Free radical pathology and antioxidant defense in schizophrenia: a review. Schizophr Res. 19:1-17.95. Tosic M, Ott J, Barral S, et al. (2006). Schizophrenia and oxidative stress: glutamate cysteine ligase modifier as a susceptibility gene. Am J Hum Genet. 79(3):586-592.96. Liebermann JA. (1999). Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective. Biol Psychiatry. 46(6):729-739.97. Gottesman II, Shields J, Hanson DR. (1982). Schizophrenia—The Epigenetic Puzzle. Cambridge University Press. Cambridge, UK.98. Petronis A, Paterson AD, Kennedy JL. (1999). Schizophrenia: An Epigenetic Puzzle? Schizophr Bull. 1999;25(4):639-655.99. Freedman R, Adler LE, Leonard S. (1999). Alternative phenotypes for the complex genetics of schizophrenia. Biol Psychiatry. 45(5):551-558.100. Petronis A, Gottesman II, Peixiang K, et al. (2003). Monozygotic twins exhibit numerous epigenetic differences: clues to twin discordance? Schizophr Bull. 29(1):169-178.101. Kundakovic M, Chen Y, Costa E, Grayson DR. (2007). DNA methyltransferase inhibitors coordinately induce expression of the human reelin and GAD67 genes. Mol Pharmacol. 71:644-653.102. Waltrip RW, Carrigan DR, Carpenter WT. (1990). Immunopathology and viral reactivation. A general theory of schizophrenia. J Nerv Ment Dis. 178(12):729-738.103. Lane N. Born to the purple: the story of porphyria. (2002, December 16). Sci Am. 104. López-Muñoz F, Bhatara VS, Alamo C. (2004). Historical approach to reserpine discovery and its introduction in psychiatry. Actas Esp Psiquiatr. 32(6):387-395.105. Schatzberg AF, Nemeroff CB. (2009). Textbook of Psychopharmacology. American Psychiatric Publishing, Inc.: Arlington VA.106. Hirschfeld RM. (2000). History and evolution of the monoamine hypothesis of depression. J Clin Psychiatry. 61(suppl 6):4-6.107. Physician’s Desk Reference 2010. Thompson PDR: Montvale, NJ.108. Fava M, Borus, JS, Alpert JE, Nierenberg AA, Rosenbaum JF, Bottiglieri T. (1997). Folate, vitamin B12, and homocysteine in major depressive disorder. Am J Psychiatry. 154(3):426-428.109. Larkin RW. (2007). Comprehending Columbine. Temple University Press: Philadelphia.110. Brewer GJ. (2000). Recognition, diagnosis, and management of Wilson’s disease. Proc Soc Exp Biol Med. 223(1)39-46.111. Crayton JW, Walsh WJ. (2007). Elevated serum copper levels in women with a history of post-partum depression. J Trace Elements Med Biol. 21:17-21.112. Klassen CD. (1996). Casarett & Doull’sToxicology, the Basic Science of Poisons. 5th ed. McGraw-Hill: New York.113. Kanner L. (1943). Autistic disturbances of affective contact. Nerv Child. 2:217-250.114. Kanner L, ed. (1973). Childhood Psychosis: Initial Studies and New Insights. V. H. Winston: Washington, DC.115. Monitoring network, United States, 2006. (2006). MMWR Surveillance Summaries. Centers for Disease Control and Prevention: Washington, DC.116. Freitag CM. (2007). The genetics of autistic disorders and its clinical relevance: a review of the literature. Mol Psychiatry. 12(1):2-22.117. Stefanatos GA. (2008). Regression in autistic spectrum disorders. Neuropsychol Rev. 18(4):305-319.118. Bettelheim B. (1967). The Empty Fortress: Infantile Autism and the Birth of the Self. The Free Press: New York.119. Walsh WJ, Usman A, Tarpey J. Disordered metal metabolism in a large autism population. Proceedings of the American Psychiatric Association. New Research: Abstract NR109; May 9, 2001, New Orleans, LA.120. Dziobek I, Bahnermann M, Convit A, Heekeren HR. (2010). The role of the fusiform amygdala system in the pathophysiology of autism. Arch Gen Psychiatry. 67(4)397-405.121. Kemper TL, Baumann M. (1998). Neuropathology of infantile autism. J Neuropathol Exp Neurol. 57:645-652.122. Bauman ML, Kemper TL. (2005). Neuroanatomic observations of the brain in autism. Int J Dev Neurosci. 23:183-187.123. Casanova MF. (2004). White matter increase and minicolumns in autism. Ann Neurol. 56:453.124. Casanova MF, Buxhoeveden D, Switala A, Roy E. (2002). Minicolumnar pathology in autism. Neurology. 58:428-432.125. Evans TA, Siedlak SL, Lu L, McGinnis W, Walsh W, et al. (2008). The autistic phenotype exhibits a remarkably localized modification of brain protein by products of free radical induced lipid oxidation. Am J Biochem Biotech. 4(2):61-72.126. Courchesne E, Carper R, Akshoomoof N. (2003). Evidence of brain overgrowth in the first year of life in autism. JAMA. 290(3):337-344.127. Vargas DL, Nascimbene C, Krishnan C, Zimmerman AW, Pardo CA. (2005). Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann Neurol. 55(2):257-267.128. Pangborn J, Baker SM. (2005). Autism: Effective Biomedical Treatments. Autism Research Institute: San Diego, CA.129. Russo AJ. (2009). Decreased serum Cu/Zn SOD in children with autism. Nutr Metab Insights. 2:27-35.130. Keenan M, Henderson M, Kerr KP, Dillenburger K, eds.. (2005). Applied Behaviour Analysis And Autism: Building a Future Together. Jessica Kingsley Publishers: London.131. Kearney AJ. (2007). Understanding Applied Behavior Anaylsis: An Introduction to ABA for Parents, Teachers, and Other Professionals. Jessica Kingsley Publishers: London.132. Barbera M, Rasmussen T. (2007). The Verbal Behavior Approach: How to Teach Children with Autism and Related Disorders. Jessica Kingsley Publishers: London.133. Hibbs ED, Jensen PS, eds. (2005). Psychosocial Treatments for Child and Adolescent Disorders: Empirically Based Strategies for Clinical Practice. 2nd ed. American Psychological Association: Washington, DC.134. Cooper JO, Heron TE, Heward WL. (2007). Applied Behavior Analysis. 2nd ed. Prentice Hall: Upper Saddle River, NJ.135. Simpson RL. (1999). Early Intervention with Children with Autism: The Search for Best Practices. J Assoc Persons with Severe Handicaps. 24(3):218-221.136. US Department of Health & Human Services. (1999). Mental Health: A Report of the Surgeon General—Executive Summary. US Department of Health & Human Services, Substance Abuse and Mental Health Services Administration, Center for Mental Health Services, National Institutes of Health, National Institute of Mental Health: Rockville, MD137. Pardo CA, Vargas DL, Zimmerman AW. (2005). Immunity, neuroglia and neuroinflammation in autism. Int Rev Psychiatry. 17(6):485.138. Reichelt KL, Knivsberg A-M, Lind G, Nødland M. (1991). Probable etiology and possible treatment of childhood autism. Brain Dysfunct. 4:308-319.139. Jain KK. (1996). Textbook of Hyperbaric Medicine. 2nd ed. Hogrefe and Huber Publishers, Inc.: Cambridge, MA.140. Walsh W (2012). Risperdal and brain shrinkage: a warning for autism families. Autism Science Digest. 4:128.141. McCracken JT, McGough J, Shah B. (2002). Risperidone in children with autism and serious behavioral problems. NEJM. 347:314-321.142. Dorph-Peterson K-A, Pierri JN, Sun Z, Sampson AR, Lewis DA (2005). The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: a comparison of haloperidol and olanzapine in macaque monkeys. Neuropsycopharmacology. 30(9): 1649-61.143. Konopaske GT, Dorph-Peterson K-A, Pierri JN, Wu Q, Sampson AR, Lewis DA (2007). Effect of chronic exposure to antipsychotic medications on cell numbers in the parietal cortex of macaque monkeys. Neuropsychopharmacology. 32(6): 1216-23.144. Konopaske GT, Dorph-Peterson K-A, Sweet RA, Pierri JN, Zhang W, Sampson AR, Lewis DA (2008). Effect of chronic antipsychotic exposure on astrocyte and oligodendrocyte numbers in macaque monkeys. Biol Psychiatry. 63(8): 759-765.145. Harrison PJ, Lewis DA (2003). Neuropathology of schizophrenia. In: Hirsch S, Weinberger DR, eds. Schizophrenia. 2nd ed. Oxford, England: Blackwell Science Ltd (310-325).146. Lewis DA (2011). Antipsychotic medications and brain volume. Do we have cause for concern? (Editorial). Arch Gen Psych, 68(2): 126-7.147. Walsh WJ, Usman AL, inventors. Nutrient Supplements and Methods for Treating Autism and for Preventing the Onset of Autism. US Patent No. 7,232,575; June 19, 2007.148. Stromland K, Nordin V, Miller M, Akerstrom B, Gilberg C. (1994). Autism in thalidomide embryopathy: a population study. Dev Med Child Neurol. 36(4):351-356.149. Tost J. (2008). Epigenetics. Chapter 16 (371-376). Caister Academic Press: Norfolk, UK.150. Walsh WJ, Glab LB, Haakenson ML. (2004). Reduced violent behavior following biochemical therapy. Physiol Behav. 82:835-839.151. Wilson JQ, Herrnstein RJ. (1985). Crime and human nature. New York: Simon and Schuster.152. Graeber MB, Mehraein P. (1999). Reanalysis of the first case of Alzheimer’s disease. Eur Arch Psychiatry Clin Neurosci. 249(suppl 3):10-13.153. Kraepelin E. (1910). Psychiatrie: Ein Lehrbuch fur Studierende und Arzte. Leipzig: Barth. 1910:593-632.154. Folstein MF, Folstein SE, McHugh PR. (1975). Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatric Res. 12(3):189-198.155. Robbins TW, James M, Owen AM, Sahakian BJ, McInnes L, Rabbitt P. (1994). Cambridge Neuropsychological Test Automated Battery (CANTAB): a factor analytic study of a large sample of normal elderly volunteers. Dementia. 5(5):266-281.156. Hoyert DL, Rosenberg HM. (1997). Alzheimer’s disease as a cause of death in the United States. Public Health Rep. 112(6):497-505.157. Campion D, Brice A, Hannequin D, et al. (1995). A large pedigree with early-onset Alzheimer’s disease: clinical, neuropathologic, and genetic characterization. Neurology. 45(1):80-85.158. Saunders AM, Schmader K, Breitner JCS, et al. (1993). Apolipoprotein E epsilon 4 allele distributions in late-onset Alzheimer’s disease and in other amyloid-forming diseases. Lancet. 342:710-711.159. Katzman R, Bick K. (2000). Alzheimer Disease: The Changing View. Academic Press: London.160. Plassman BL, Havlik RJ, Steffens DC, et al. (2000). Documented head injury in early adulthood and risk of Alzheimer’s disease and other dementias. Neurology. 55(8):1158-1166.161. Roberts AH. (1969). Brain Damage in Boxers. Pitman Medical Scientific Publishing Co.: London.162. Roe CM, Mintun MA, D’Angelo G, Xiong C, Grant EA, Morris JC. (2008). Alzheimer’s disease and cognitive reserve. Arch Neurol. 65(11):1467-1471.163. Scarmeas N. (2006). Education and rates of cognitive decline in incident Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 77:308-316.164. Wilson RS, Mendes de Leon CF, Barnes LI, et al. Participation in cognitively stimulating activities and risk of incident Alzheimer disease. JAMA. Feb 13, 2002.165. Larson EB. (2008). Physical activity for older adults at risk for Alzheimer disease. JAMA. 300(9):1077-1079.166. Mielke MM, Rosenberg PB, Tschanz J, et al. (2007). Vascular factors predict rate of progression in Alzheimer disease. Neurology. 69:1850-1858.167. Truelsen T, Thudium D, Gronbaek M. (2002). Amount and type of alcohol and risk of dementia: The Copenhagen Heart Study. Neurology. 59:1313-1319.168. Mruthinti S, Schade RF, Harrell DU, et al. (2006). Autoimmunity in Alzheimer’s Disease as evidenced by plasma immunoreactivity against RAGE and Aβ42: complication of diabetes. Curr Alzheimer Res. 3(3):229-235.169. Cornett CR, Markesbery WR, Ehmann WD. (1998). Imbalances of trace elements related to oxidative damage in Alzheimer’s disease brain. Neurotoxicity. 19:339-346.170. Solfrizzi V, Panza F, Capurso A. (2003). The role of diet in cognitive decline. J Neural Trans. 110:95-110.171. Seshadri S, Beiser A, Selhub J, et al. (2002). Plasma homocysteine as a risk factor for dementia and Alzheimer’s disease. NEJM. 346:476-483.172. Boiler F, Forette F. (1989). Alzheimer’s disease and THA: a review of the cholinergic theory and of preliminary results. Biomed Pharmacother. 43(7):487-491.173. Davis KL, Mohs RC, Marin D, et al. (1999). Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA. 281(15):1401-1406.174. Shankar GM, Li S, Mehta TH, et al. (2008). Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory. Nat Med. 14(8):837-842.175. Hartmann T, Bieger SC, Brühl B, et al. (1997). Distinct sites of intracellular production for Alzheimer’s disease A beta40/42 amyloid peptides. Nat Med. 3(9):1016-1020.176. Schenk D, Barbour R, Dunn W, et al. (1999). Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 400:173-177.177. Town T. (2009). Alternative Aβ immunotherapy approaches for Alzheimer’s disease. CNS Neurol Disord Drug Targets. 8(2):114-127.178. Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E. (1995). Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol. 26(3)231-245.179. Zhang Q, Powers ET, Nieva J, et al. (2004). Metabolite-initiated protein misfolding may trigger Alzheimer’s disease. Proc Natl Acad Sci. 101(14):4752-4757.180. Markesbery WR. (1997). Oxidative stress hypothesis in Alzheimer’s disease. Free Radic Biol Med. 23(1):134-147.181. Perry G, Cash AD, Smith MA. (2002). Alzheimer disease and oxidative stress. J Biomed Biotechnol. 2(3):120-123.182. Lee HP, Zhu X, Casadesus G, et al. (2010). Antioxidant approaches for the treatment of Alzheimer’s disease. Expert Rev Neurother. 10(7):1201-1208.183. Hung YH, Bush AI, Cherny RA. (2010). Copper in the brain and Alzheimer’s disease. J Biol Inorg Chem. 15(1):61-76.184. House E, Mold M, Collingwood J, Baldwin A, Goodwin S, Exley C. (2009). Copper Abolishes the β-Sheet Secondary Structure of Preformed Amyloid Fibrils of Amyloid-β. J Alzheimer’s Dis. 18:811-817.185. Yang XH, Huang HC, Chen L, Xu W, Jiang ZF. (2009). Coordinating to three histidine residues: Cu(II) promotes oligomeric and fibrillar amyloid-β peptide to precipitate in a non-β aggregation way. J Alzheimer’s Dis. 18(4):799-810.186. Walsh WJ, Lai B, Bazan N, Lukiw WL. (March 1, 2005). Trace metal analysis in Alzheimer’s disease tissues using high-brilliance x-ray beams. Proceedings of the 6th Keele Meeting on Trace Metals and Neurotoxicity in the Brain. Portugal.187. Yu WH, Lukiw WJ, Bergeron C, Niznik HB, Fraser PE. (2001). Metallothionein III is reduced in Alzheimer’s disease. Brain Res. 894(1):37-45.188. Uchida Y, Takio K, Titani K, Ihara Y, Tomonaga M. (1991). The growth inhibitory factor that is deficient in the Alzheimer’s-disease brain is a 68-amino acid metallothionein-like protein. Neuron. 7(2):337-347.189. LaRowe SD, Myrick H, Kalivas PW, et al. (2007). Is cocaine desire reduced by N acetylcysteine? Am J Psychiatry. 164:1115-1117.190. Vengeliene V, Kiefer F, Spanagel R. (2011). D-cycloserine facilitates extinction of alcohol seeking behavior in rats. Alcohol and Alcoholism. 43(6):626-629.191. Lovinger DM, White G, Weight FF. (1989). Ethanol inhibits NMDA-activated ion current in hippocampal neurons. Science. 243(4899):1721-1724.
Dominic: I'm embedding below the page from my website which I created with research I found relevant, so as to ensure easy syncing. Some of these are referenced above.